ライフサイエンスコーパス: efavirenz

1 95% CI, 1.4-2.7; log rank P < .001, favoring efavirenz).

2 but not to the assignment of cabotegravir or efavirenz.

3 y 46%, consistent with induction of CYP3A by efavirenz.

4 suicidality compared with a regimen without efavirenz.

5 e/zidovudine plus lamivudine plus nevirapine/efavirenz.

6 cellent compared with that of compound I and efavirenz.

7 ng and not receiving emtricitabine/tenofovir/efavirenz.

8 ed with 5% of patients (18 of 338) receiving efavirenz.

9 unliganded RT, is dramatically suppressed by efavirenz.

10 ltered H/D exchange rates in the presence of efavirenz.

11 cokinetics of single doses of nevirapine and efavirenz.

12 s and the pharmacokinetics of nevirapine and efavirenz.

13 ic tablets with lamivudine and nevirapine or efavirenz.

14 ransgenic mice chronically administered with efavirenz.

15 rine (16% [54 patients]) than they were with efavirenz (31% [104]; p<0.0001), as were rash and dizzin

16 Of 28 subjects (14 and 14 on efavirenz 400 mg and 600 mg, respectively), CSF HIV RNA

17 misuse of the HIV antiretroviral medication efavirenz ((4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(tri

18 g once a day; each allocation was given with efavirenz 600 mg once a day and lamivudine 300 mg once a

19 30 mg once a day, 60 mg once a day, or oral efavirenz 600 mg once a day with dual nucleoside reverse

20 receive oral rilpivirine 25 mg once daily or efavirenz 600 mg once daily; all patients received an in

21 tenofovir 300 mg, emtricitabine 200 mg, and efavirenz 600 mg) and achieving VS (<50 copies/mL).

22 previr (240 mg twice daily) with and without efavirenz (600 mg once daily); or (3) faldaprevir (240 m

23 g) or to continue a single-tablet regimen of efavirenz (600 mg), emtricitabine (200 mg), and tenofovi

24 Efavirenz (600 mg/d) and stavudine plus lamivudine were

25 Geometric mean CSF efavirenz, 7OH-, and 8OH-efavirenz concentrations (with

26 nnucleoside reverse transcriptase inhibitor (efavirenz), a ritonavir-boosted protease inhibitor (ataz

27 Efavirenz affects the bioenergetics of neurons through a

28 avirenz plus antituberculosis drugs) and 50 (efavirenz alone) after initiation of antituberculosis tr

29 Efavirenz alters mitochondrial respiration, enhances rea

30 % CI, 10.4%-17.2%) initiating treatment with efavirenz and 101 children (26.4%; 95% CI, 22.0%-31.1%)

31 ricitabine was 2.35 (95% CI, 1.61-3.42) with efavirenz and 2.01 (95% CI, 1.36-2.98) with nevirapine.

32 children (2.6%; 95% CI, 1.3%-4.6%) receiving efavirenz and 20 children (5.2%; 95% CI, 3.2%-7.9%) rece

33 z apparent clearance in patients taking both efavirenz and antituberculosis treatment was highly depe

34 tly prescribed antiretroviral drugs, such as efavirenz and boosted HIV protease inhibitors.

35 d plasma and breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in human immun

36 us ritonavir and and the group that received efavirenz and did not differ according to whether abacav

37 2.90 (17 events) and 1.22 (5 events) in the efavirenz and efavirenz-free groups, respectively (hazar

38 de reverse transcriptase inhibitors (NNRTIs) efavirenz and nevirapine are commonly used in first-line

39 nt additional research evaluating the use of efavirenz and nevirapine for pediatric patients.

40 TH, FGF-23, of F2-isoprostane levels between efavirenz and PI use or between those receiving and not

41 nnucleoside reverse transcriptase inhibitors efavirenz and rilpivirine, ritonavir-boosted lopinavir,

42 r cytotoxicity than the approved NNRTI drugs efavirenz and rilpivirine.

43 e mutation, does not prevent binding between efavirenz and RT-T/P but instead allows formation of a s

44 Cerebrospinal fluid (CSF) exposure of efavirenz and the metabolites 7-hydroxy (7OH) and 8-hydr

45 intake at weeks 2 and 6 after initiation of efavirenz and weeks 22 (efavirenz plus antituberculosis

46 e subjective experiences in humans who abuse efavirenz and with specific dose-dependent adverse neuro

47 ich is similar to that for the approved drug efavirenz and ~1000-fold greater than for rilpivirine.

48 t-Naive, HIV-Infected Subjects of TMC278 and Efavirenz) and THRIVE (TMC278 Against HIV, in a Once-Dai

49 re 528, 280, and 710 pg/mL in the ART-naive, efavirenz, and nevirapine groups, respectively (efaviren

50 re 580, 247, and 664 pg/mL in the ART-naive, efavirenz, and nevirapine groups, respectively (efaviren

51 ly used antiretrovirals darunavir/ritonavir, efavirenz, and tenofovir to guide the coadministration o

52 Change in efavirenz apparent clearance in patients taking both efa

53 ow-acetylation NAT2 phenotype had the lowest efavirenz apparent clearance.

54 Median efavirenz apparent oral clearance was 9.3 L/hour (IQR, 6

55 Efavirenz apparent oral clearance was estimated and the

56 virenz, and nevirapine groups, respectively (efavirenz: ART-naive GMR, 0.43; 90% CI, .42, .44 and nev

57 virenz, and nevirapine groups, respectively (efavirenz: ART-naive GMR, 0.53; 90% CI, .50, .55 and nev

58 Advantages of using efavirenz as part of treatment for children infected wit

59 ne tenofovir DF-associated mutation and four efavirenz-associated mutations were detected in particip

60 commence antiretroviral regimens containing efavirenz at either 400 mg or 600 mg once daily.

61 activity, which was non-inferior to that of efavirenz at week 48.

62 tiretrovirals were tenofovir, emtricitabine, efavirenz, atazanavir, and raltegravir.

63 Efavirenz AUCs increased 1.26-fold per doubling of the a

64 ted with 12-month depression, but receipt of efavirenz-based antiretroviral therapy is not.

65 the risk of virologic failure of first-line efavirenz-based antiretroviral therapy.

66 -infected Ugandan women: ART-naive (n = 17), efavirenz-based ART (n = 20), and nevirapine-based ART (

67 s, between the lopinavir/ritonavir-based and efavirenz-based ART arms (7.4% vs 9.8%; P = .45).

68 though HIV-positive women using implants and efavirenz-based ART had a three-times higher risk of con

69 s and 3.3 per 100 person-years (1.8-4.8) for efavirenz-based ART users (adjusted incidence rate ratio

70 s and 5.4 per 100 person-years (4.0-6.8) for efavirenz-based ART users (adjusted IRR 1.2, 95% CI 0.91

71 arkedly reduced in participants who received efavirenz-based ART, accompanied by contraceptive failur

72 gned to receive lopinavir/ritonavir-based or efavirenz-based ART.

73 ria or improve birth outcomes, compared with efavirenz-based ART.

74 ts, with 1.6-2.8 higher rates in women using efavirenz-based ART.

75 Raltegravir and efavirenz-based initial antiretroviral therapy have simi

76 use various contraceptive methods and either efavirenz-based or nevirapine-based antiretroviral thera

77 as a combination of contraceptive method and efavirenz-based or nevirapine-based ART regimen.

78 terol levels at 3 years compared to those on efavirenz-based regimens (13.6 vs 9.5 mg/dL, P = .01).

79 icipants were randomly assigned to switch to efavirenz-based therapy (n = 150) or continue ritonavir-

80 oosted lopinavir-based therapy, switching to efavirenz-based therapy compared with continuing ritonav

81 Dimerization and efavirenz binding are coupled processes.

82 The effects of efavirenz binding extend > 60 A from the NNRTI binding p

83 exchange mass spectrometry (HXMS) shows that efavirenz binding reduces molecular flexibility in multi

84 s ritonavir and 465 were assigned to receive efavirenz, both with abacavir-lamivudine; 322 (70%) and

85 with plasma drug exposure and clearance for efavirenz but not nevirapine.

86 Among studied drugs, Efavirenz, but not other NNRTIs, altered claudin-5 expre

87 s or treatment), though, reduced the rate of efavirenz clearance.

88 -dependant inhibitory effect of isoniazid on efavirenz clearance.

89 sed method was applied to data from an HIV-1 Efavirenz clinical trial study.

90 Median efavirenz Cmin during pregnancy was 1.35 microg/mL (inte

91 range [IQR], 0.90-2.07 microg/mL; 27% had an efavirenz Cmin of < 1 microg/mL), compared with a median

92 rog/mL (IQR, 1.40-3.59 microg/mL; 13% had an efavirenz Cmin of < 1 microg/mL).

93 women with extensive CYP2B6 genotypes had an efavirenz Cmin of <1 microg/mL.

94 Rifampin did not reduce the efavirenz Cmin.

95 treated at a clinic in Botswana, the use of efavirenz compared with nevirapine as initial antiretrov

96 ss-resistance to etravirine, nevirapine, and efavirenz compared with wild type HIV-1 plasma-derived c

97 Efavirenz concentration in CSF was >0.51 ng/mL (proposed

98 or wild-type virus) in all subjects, and 8OH-efavirenz concentration in CSF was >3.3 ng/mL (a propose

99 rve (AUC) to assess short-term exposure; the efavirenz concentration in hair was measured to estimate

100 mean ratio, 0.56 [90% CI, .42-.74]), CSF 8OH-efavirenz concentration was not (P = .242 for associatio

101 Whereas CSF efavirenz concentration was significantly associated wit

102 ocytes were treated with clinically relevant efavirenz concentration.

103 proportion of participants with midinterval efavirenz concentrations >/=1 mg/L did not cross below t

104 Numbers of participants with efavirenz concentrations >/=1 mg/L were 85 (98%) at week

105 Geometric mean CSF efavirenz, 7OH-, and 8OH-efavirenz concentrations (with 90% confidence intervals

106 I] 1.52, 38.30; p = 0.01) with nevirapine or efavirenz concentrations above vs. below the median meas

107 s were each associated with increased plasma efavirenz concentrations during antituberculosis therapy

108 2B6 516G>T was independently associated with efavirenz concentrations in maternal plasma, breast milk

109 Pregnancy increased the risk of low efavirenz concentrations, but MTCT was rare.

110 y, participants were randomly assigned to an efavirenz-containing (n = 3241) or efavirenz-free (n = 2

111 Initial treatment with an efavirenz-containing antiretroviral regimen was associat

112 ssociated with reduced virologic response to efavirenz-containing multidrug regimens.

113 mly assigned treatment-naive participants to efavirenz-containing regimens; suicidality was defined a

114 sociated with inferior HIV-1 RNA response to efavirenz-containing therapy between entry and week 24 (

115 tant variants at the initiation of multidrug efavirenz-containing therapy in both NNRTI-naive and NNR

116 r superior to first-line regimens containing efavirenz, darunavir/ritonavir, or raltegravir regardles

117 Efavirenz decreased faldaprevir area under the concentra

118 76 of 338) who received at least one dose of efavirenz (difference 3.5% [95% CI -1.7 to 8.8]; p(non-i

119 At the same time, efavirenz diminished autophagic activity, a surprising r

120 The estimated maximum infant efavirenz dose from breast milk was 809 microg/kg/day (2

121 s of further experiments, we identified that efavirenz dysregulated ER stress and autophagy by blocki

122 Open-label atazanavir plus ritonavir or efavirenz, each given with with placebo-controlled abaca

123 DF/ emtricitabine (FTC)/NVP (n = 9), TDF/3TC/efavirenz (EFV) (n = 6), and TDF/FTC/EFV (n = 19).

124 rotease changes compared with those assigned efavirenz (EFV) (P >/= .13).

125 anti-human immunodeficiency virus (HIV) drug efavirenz (EFV) alters mitochondrial function in culture

126 utations K101E+G190S are highly resistant to efavirenz (EFV) and can develop during failure of EFV-co

127 pine (NVP) and delavirdine (DLV), but not to efavirenz (EFV) and etravirine (ETR), consistent with th

128 ide reverse transcriptase inhibitors (NNRTI) efavirenz (EFV) and nevirapine (NVP) in first-line antir

129 Previously, we found that the anti-HIV drug efavirenz (EFV) can pharmacologically activate CYP46A1 i

130 nal cells from the excitotoxic insult, while efavirenz (EFV) did not contrast the neurotoxic effect o

131 tes CYP 450 isoenzymes, potentially lowering efavirenz (EFV) exposure.

132 nses to atazanavir plus ritonavir (ATV/r) or efavirenz (EFV) in initial antiretroviral regimens among

133 Efavirenz (EFV) is a nonnucleoside reverse transcriptase

134 Three animals received a short course of efavirenz (EFV) monotherapy before combination ART was s

135 after they were exposed to a short course of efavirenz (EFV) monotherapy.

136 ith tenofovir (TDF)-emtricitabine (FTC) with efavirenz (EFV) or atazanavir plus ritonavir (ATV/r), on

137 us tenofovir DF-emtricitabine (TDF/FTC) with efavirenz (EFV) or atazanavir-ritonavir (ATV/r).

138 to tenofovir DF/emtricitabine (TDF/FTC) with efavirenz (EFV) or atazanavir/ritonavir (ATV/r) in human

139 current study was conducted to determine if efavirenz (EFV) or atazanavir/ritonavir (ATV/r)-based co

140 ll paired with lamivudine or emtricitabine): efavirenz (EFV) plus zidovudine (AZT) (n = 524); EFV plu

141 Compared with no ART, efavirenz (EFV) reduced exposure to all antimalarial com

142 side reverse transcriptase inhibitor (NNRTI) efavirenz (EFV) showed subunit-specific perturbation in

143 We compared the effect of switching efavirenz (EFV) to raltegravir (RAL) on hepatic steatosi

144 onstrated the noninferiority of switching to efavirenz (EFV) versus remaining on ritonavir-boosted lo

145 The distribution of efavirenz (EFV) was then monitored in a series of hair s

146 In the presence of efavirenz (EFV), a virus carrying RT-K103N together with

147 We found that four pharmaceuticals (efavirenz (EFV), acetaminophen, mirtazapine, and galanta

148 ta were compared to historical estimates for efavirenz (EFV)- and ritonavir/lopinavir (LPV/r)-based r

149 /FTC/TDF with standard of care-co-formulated efavirenz (EFV)/FTC/TDF-as initial treatment for HIV inf

150 3N, V106M, and M184V with failure of d4T/3TC/efavirenz (EFV; P < .01).

151 suppressed (HIV-1 RNA <50 copies per mL) on efavirenz, emtricitabine, and tenofovir disoproxil fumar

152 events compared with 45 (10%) of 437 in the efavirenz, emtricitabine, and tenofovir disoproxil fumar

153 mtricitabine, and tenofovir alafenamide from efavirenz, emtricitabine, and tenofovir disoproxil fumar

154 imen compared with remaining on coformulated efavirenz, emtricitabine, and tenofovir disoproxil fumar

155 copies per mL or more, and susceptibility to efavirenz, emtricitabine, and tenofovir.

156 bine, and tenofovir alafenamide and 437 with efavirenz, emtricitabine, tenofovir disoproxil fumarate)

157 delines recommend branded once-daily, 1-pill efavirenz-emtricitabine-tenofovir as first-line antiretr

158 proxil fumarate (EVG/c/FTC/TDF) with that of efavirenz/emtricitabine/tenofovir disoproxil fumarate (E

159 tigates the BMD loss seen with initiation of efavirenz/emtricitabine/tenofovir disoproxil fumarate.

160 ide reverse transcriptase inhibitors (NNRTI; Efavirenz, Etravirine, Rilpivirine and Nevirapine) on th

161 Efavirenz exhibits marked interindividual variability in

162 uicidality and genotypes that predict plasma efavirenz exposure among AIDS Clinical Trials Group stud

163 Importantly, Efavirenz exposure increased the severity of stroke in a

164 Genotypes that predict higher plasma efavirenz exposure were associated with increased risk o

165 Genotypes that predict plasma efavirenz exposure were defined by CYP2B6 and CYP2A6 pol

166 d increases in both short-term and long-term efavirenz exposure, signifying durable effects.

167 rphisms in CYP2B6, ABCB1, and CYP3A5; plasma efavirenz exposure; and/or treatment responses.

168 porter 2 (like cocaine and methamphetamine), efavirenz fails to maintain responding in rats that self

169 that included tenofovir, emtricitabine, and efavirenz for 48 weeks.

170 that included tenofovir, emtricitabine, and efavirenz for 48 weeks.

171 ned to an efavirenz-containing (n = 3241) or efavirenz-free (n = 2091) regimen.

172 efavirenz group and 3.66 (15 events) in the efavirenz-free group (hazard ratio, 2.28 [95% CI, 1.27 t

173 suicides in the efavirenz group and 1 in the efavirenz-free group were reported.

174 ts) and 1.22 (5 events) in the efavirenz and efavirenz-free groups, respectively (hazard ratio, 2.58

175 Efavirenz versus efavirenz-free regimens.

176 s, a once-daily, 3-pill alternative (generic efavirenz, generic lamivudine, and tenofovir) will decre

177 .001) and cytochrome P450 2B6 genotype (CSF efavirenz GG to GT/TT geometric mean ratio, 0.56 [90% CI

178 as not (P = .242 for association and CSF 8OH-efavirenz GG to GT/TT geometric mean ratio, 1.52 [90% CI

179 s of viral failure were 0.027 (n = 4) in the efavirenz group and 0.020 (n = 3) in the ritonavir-boost

180 ebound by 48 weeks was 0.176 (n = 26) in the efavirenz group and 0.284 (n = 42) in the ritonavir-boos

181 Eight suicides in the efavirenz group and 1 in the efavirenz-free group were r

182 000 person-years was 8.08 (47 events) in the efavirenz group and 3.66 (15 events) in the efavirenz-fr

183 hree pregnancies (3/20, 15%) occurred in the efavirenz group between weeks 36 and 48.

184 in the rilpivirine group and 7% (25) in the efavirenz group discontinued treatment due to adverse ev

185 ups, respectively) and 46 (74%) of 62 in the efavirenz group had fewer than 50 copies per mL of HIV-1

186 as 2.88% (95% CI, 1.26%-4.49%) higher in the efavirenz group than in the ritonavir-boosted lopinavir

187 respectively) versus 44 (71%; 60-82) in the efavirenz group were virologically suppressed at week 48

188 respectively) versus 39 (63%; 51-75) in the efavirenz group were virologically suppressed at week 96

189 verse events compared with nine (15%) in the efavirenz group.

190 howed measurable nevirapine (>0.25 ng/ml) or efavirenz (>5 ng/ml) concentrations, respectively.

191 ceiving daily rifapentine and isoniazid with efavirenz had pharmacokinetic evaluations at baseline an

192 e-daily darunavir, once-daily darunavir, and efavirenz had the highest CSF 95% inhibitory quotients (

193 Atazanavir plus ritonavir and efavirenz have similar antiviral activity when used with

194 r, it attenuated resistance to nevirapine or efavirenz imparted by NNRTI mutations.

195 ion pharmacokinetics and pharmacogenetics of efavirenz in 307 patients coinfected with human immunode

196 ns), we have captured RT bound to the NNRTI efavirenz in a closed conformation similar to that of th

197 eland), had equivalent sustained efficacy to efavirenz in a phase 2b trial in treatment-naive patient

198 to assess non-inferiority of rilpivirine to efavirenz in a phase 3 trial with common background nucl

199 rns about possible reduced viral efficacy of efavirenz in children exposed to nevirapine for preventi

200 With the anticipated approval of generic efavirenz in the United States, a once-daily, 3-pill alt

201 ranscriptase inhibitor (NNRTI; nevirapine or efavirenz) in sub-Saharan Africa.

202 ricitabine, lamivudine, and indinavir), only efavirenz increased ER stress via upregulation and activ

203 Similar to LSD, efavirenz induces head-twitch responses in wild-type, bu

204 mples were obtained a mean of 14 hours after efavirenz intake at weeks 2 and 6 after initiation of ef

205 The main side effects attributed to efavirenz involve the CNS, but the underlying mechanisms

206 Efavirenz is a second-generation nonnucleoside reverse t

207 These results show that efavirenz is a slow, tight-binding inhibitor capable of

208 We rejected the null hypothesis that efavirenz is inferior to ritonavir-boosted lopinavir (P

209 pulation of HIV-infected individuals in whom efavirenz is not fully effective.

210 ive antiretroviral therapy (HAART) including efavirenz is recommended as a 1(st)-line treatment choic

211 The antiretroviral drug efavirenz is widely used during breastfeeding.

212 Among participants on efavirenz, K103N was the most frequently observed resist

213 Current exposure to abacavir, efavirenz, lamivudine, and zidovudine was significantly

214 One of these-efavirenz, lamivudine, and zidovudine-was the second mos

215 shorter for patients on raltegravir than on efavirenz (log-rank test p<0.0001).

216 tained at doses below the approved dose (eg, efavirenz, lopinavir plus ritonavir, atazanavir, and dar

217 file and non-inferior efficacy compared with efavirenz means that rilpivirine could be a new treatmen

218 without clinically meaningful reductions in efavirenz mid-dosing concentrations or virologic suppres

219 n the changes in FMD between those receiving efavirenz [N = 12; -3.50% (-4.90%, 0.68%)] vs. protease

220 icitabine-tenofovir-disoproxil fumarate plus efavirenz, n = 278) as part of the ACTG PEARLS study (A5

221 reatment arms: A (lamivudine-zidovudine plus efavirenz, n = 289), B (atazanavir, emtricitabine, and d

222 ts to two different nucleoside regimens with efavirenz, nelfinavir, or both.

223 t-line antiretroviral (ARV) drugs, including efavirenz, nevirapine, and lamivudine, with nucleoside r

224 HIV-1 susceptibility was reduced in 93% for efavirenz/nevirapine, in 81% for lamivudine/emtricitabin

225 Efavirenz occasions drug-lever responding in rats discri

226 Here we identified this allosteric site for efavirenz on CYP46A1 by using a combination of hydrogen-

227 e effect of the integrase inhibitor EVG over efavirenz on immune activation, which may affect vascula

228 oral raltegravir twice daily or 600 mg oral efavirenz once daily, in combination with tenofovir and

229 lus lamivudine or emtricitabine) with either efavirenz or nevirapine.

230 nnucleoside reverse transcriptase inhibitor (efavirenz or rilpivirine) or a boosted protease inhibito

231 ed to have resistance to regimens containing efavirenz or rilpivirine, respectively, independent of c

232 inhibition can contribute to the toxicity of efavirenz or the development of neurodegenerative diseas

233 We assessed the effect of efavirenz- or nevirapine-based antiretroviral therapy (A

234 in the rebound viremia after interruption of efavirenz- or nevirapine-based ART affects outcomes once

235 d with monitoring of hair levels may improve efavirenz outcomes and reduce toxicities.

236 y lower with rilpivirine than they were with efavirenz (p<0.0001).

237 2B6 516G>T (n = 29 ; 11 GG, 10 GT and 8 TT), efavirenz pharmacokinetic parameters in plasma and breas

238 rculosis treatment or prophylaxis can affect efavirenz pharmacokinetics, maternal human immunodeficie

239 ar profiling of the receptor pharmacology of efavirenz pinpointed interactions with multiple establis

240 after initiation of efavirenz and weeks 22 (efavirenz plus antituberculosis drugs) and 50 (efavirenz

241 irine provided antiviral activity similar to efavirenz plus dual NRTIs until the end of week 96.

242 sine-EC plus emtricitabine (ATV+DDI+FTC), or efavirenz plus emtricitabine-tenofovir-disoproxil fumara

243 ty to open-label antiretroviral therapy with efavirenz plus lamivudine-zidovudine (EFV+3TC-ZDV), ataz

244 ose plus oral rilpivirine 25 mg or continued efavirenz plus NRTIs for an additional 72 weeks.

245 previr (750 mg or 1125 mg every 8 hours with efavirenz) plus peg-IFN/RBV for 12 weeks and peg-IFN/RBV

246 Further, efavirenz promotes formation of the E138-K101 salt bridg

247 Compared with efavirenz, protease inhibitors were associated with high

248 ure, we reanalyzed a case-cohort substudy of efavirenz recipients in AIDS Clinical Trials Group proto

249 Both LSD and efavirenz reduce ambulation in a novel open-field enviro

250 Concerns have been raised about efavirenz reducing the effectiveness of contraceptive im

251 combination of tenofovir, emtricitabine, and efavirenz) regardless of CD4 cell count (intervention) o

252 egravir regimen compared to 2646 starting an efavirenz regimen (both regimens include emtricitabine a

253 No efavirenz related toxicity was reported.

254 One patient developed new efavirenz resistance after reinitiation of antiretrovira

255 randomized to the 400 mg and 600 mg doses of efavirenz, respectively.

256 regimen of tenofovir and emtricitabine with efavirenz, rilpivirine, or raltegravir.

257 acid diethylamine (LSD), appears to dominate efavirenz's behavioral profile.

258 its molecular pharmacology is multifarious, efavirenz's prevailing behavioral effect in rodents is c

259 With both doses of efavirenz studied, CSF concentrations were considered ad

260 tions of existing atazanavir, ritonavir, and efavirenz suspensions in order to establish cell and tis

261 ovir disoproxil fumarate, emtricitabine, and efavirenz (TDF-FTC-EFV) (901 of 2472 [36.4%]) compared w

262 Among studied drugs (efavirenz, tenofovir, emtricitabine, lamivudine, and ind

263 copies per mL, and no baseline resistance to efavirenz, tenofovir, or emtricitabine.

264 ctive through 48 weeks than the regimen with efavirenz-tenofovir DF-emtricitabine.

265 G-ABC-3TC group) or combination therapy with efavirenz-tenofovir disoproxil fumarate (DF)-emtricitabi

266 re at week 48 compared to emtricitabine with efavirenz/tenofovir (10.8% vs 3.6%; adjusted odds ratio

267 ) initiated lamivudine or emtricitabine with efavirenz/tenofovir or nevirapine/tenofovir.

268 ly by some marketed drugs, as exemplified by efavirenz, the anti-HIV medication.

269 creased plasma clearance over compound I and efavirenz, the standard of care NNRTI.

270 the influence of concomitant nevirapine vs. efavirenz, therapy duration, and HIV-1 subtype on the pr

271 Regardless of concomitant nevirapine vs. efavirenz, therapy duration, or subtype, tenofovir was m

272 posure was observed when coadministered with efavirenz; this decrease can be managed using the higher

273 ansition from first-line regimens containing efavirenz to regimens containing dolutegravir formulatio

274 The binding of efavirenz to wild-type and dimerization-defective RT pro

275 and 60 mg groups, respectively) and 42 (68%) efavirenz-treated patients.

276 Against HIV, in a Once-Daily Regimen Versus Efavirenz) trials.

277 Efavirenz trough concentrations (Cmin) were predicted us

278 armacokinetic studies in 111 women receiving efavirenz under actual-use conditions and calculated the

279 The relationship between efavirenz use and suicidality is not well-defined.

280 ticipants (2:1; blocks of six, stratified by efavirenz use at screening) to switch to coformulated el

281 Efavirenz use was associated with reduced FMD at 12 mont

282 Efavirenz versus efavirenz-free regimens.

283 < 0.001; OR = 17.6 [3.26-95.3], P < 0.0001); efavirenz was associated with nonspecific hepatitis or s

284 based regimens while emtricitabine/tenofovir/efavirenz was associated with reduced FMD at both 6 and

285 CSF exposure of 8OH-efavirenz was not dependent on plasma exposure and, as w

286 Efavirenz was open-label in 3 of 4 studies.

287 A 600-mg oral dose of efavirenz was subsequently administered, and pharmacokin

288 abolites 7-hydroxy (7OH) and 8-hydroxy (8OH) efavirenz were assessed after at least 12 weeks of thera

289 neuroinflammatory disorders, the effects of efavirenz were evaluated in the presence of exogenous ni

290 replication, although concentrations of 8OH-efavirenz were greater than those reportedly associated

291 ng and not receiving emtricitabine/tenofovir/efavirenz were more pronounced and were significantly di

292 concentrations (lamivudine, nevirapine, and efavirenz) were measured on stored samples preswitch.

293 e third drugs, atazanavir plus ritonavir and efavirenz, were open-label; the nucleoside reverse trans

294 he presence of antiretrovirals tenofovir and efavirenz whereas infections involving cell-to-cell spre

295 with high-level resistance to nevirapine or efavirenz, whereas only 27% of NRTI SDRMs were associate

296 el, the reverse transcriptase (RT) inhibitor efavirenz, which is thought to promote Gag-Pol dimerizat

297 tazanavir plus ritonavir than in those given efavirenz with abacavir-lamivudine but not with tenofovi

298 We studied the interaction of efavirenz with daily rifapentine and isoniazid in human

299 ceive atazanavir/ritonavir (atazanavir/r) or efavirenz, with tenofovir/emtricitabine or abacavir/lami

300 ne plus isoniazid can be coadministered with efavirenz without clinically meaningful reductions in ef